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Background: Cell-based therapy may hold promise for treatment of chronic pain. Mesenchymal stem cells (MSCs)
are readily available and robust, and their secretion of therapeutic peptides can be enhanced by genetically
engineering. We explored the analgesic potential of transplanting bone marrow-derived MSCs that have been
transduced with lentivectors. To optimize efficacy and safety, primary sensory neurons were targeted by MSC
injection into the dorsal root ganglia (DRGs).
Results: MSCs were transduced using lentivectors to express enhanced green fluorescent protein (EGFP) or to
co-express the analgesic peptide glial cell line-derived neurotrophic factor (GDNF) and EGFP by a viral 2A bicistronic
transgene cassette. Engineered MSCs were injected into the 4th lumbar (L4) and L5 DRGs of adult allogeneic rats to
evaluate survival in the DRGs. MSCs were detected by immunofluorescence staining up to 2–3 weeks after injection,
distributed in the extracellular matrix space without disrupting satellite glial cell apposition to sensory neurons,
suggesting well-tolerated integration of engrafted MSCs into DRG tissue. To examine their potential for inhibiting
development of neuropathic pain, MSCs were injected into the L4 and L5 DRGs ipsilateral to a spinal nerve
ligation injury. Animals injected with GDNF-engineered MSCs showed moderate but significant reduction in mechanical
allodynia and hyperalgesia compared to controls implanted with MSCs expressing EGFP alone. We also observed
diminished long-term survival of allografted MSCs at 3 weeks, and the development of a highly-proliferating population
of MSCs in 12% of DRGs after transplantation.
Conclusions: These data indicate that genetically modified MSCs secreting analgesic peptides could potentially be
developed as a novel DRG-targeted cell therapy for treating neuropathic pain. However, further work is needed to
address the challenges of MSC survival and excess proliferation, possibly with trials of autologous MSCs, evaluation of
clonally selected populations of MSCs, and investigation of regulation of MSC proliferation.
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LentivectorIntroduction
Cell-based therapy has been proposed as a novel approach
for treating painful peripheral neuropathy [1,2]. Trans-
plantation of mesenchymal stem cells (MSCs) has been
demonstrated to be a potentially therapeutic approach for
the alleviation of chronic pain from various etiologies
[2-8]. Prior studies have reported pain relief in rodent
chronic pain models using systemic administration of* Correspondence: hyu@mcw.edu
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unless otherwise stated.MSCs [4,8], but this delivery approach requires large
preparations of transplantable cells, depends on a nebu-
lously defined propensity of MSCs to home in on in-
jured tissue, and leads to MSCs trapping in the lung,
liver, resulting in off-site tissue damage [9,10], making
targeted delivery preferable. Injection of MSCs into the
cerebral ventricle or subarachnoid space of mice and
rats reduces neuropathic pain from nerve injury [11,12].
However, involving the central nervous system imposes
difficulties for safe translation to human use. In con-
trast, dorsal root ganglia (DRGs), which harbor the sen-
sory neuron somata, tolerate injections in rodents andis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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important site of posttraumatic pain pathology [15,16],
it has not been developed as a site of cell therapy for
pain. A DRG-targeted MSCs delivery approach has the
benefits of tissue-specific delivery, reduced systemic side
effects, and small total load of implanted cells.
A further enhancement of MSC-based therapy can be
achieved by incorporating genetic engineering. Although
native MSCs secrete a broad range of anti-inflammatory
and neuromodulatory factors, only very low levels are pro-
duced [17,18]. Genetic manipulation provides delivery of
high concentrations of therapeutic peptides selected for
specific treatment of chronic pain resulting from different
etiologies [19]. Since the MSCs are transduced in vitro,
the benefits of genetic-based therapy are provided without
exposing the patient to viral vectors. In trials using MSCs
to treat inflammatory conditions in rat models, including
painful arthritis, MSCs modified to enhance secretion of
anti-inflammatory products resulted in successful treat-
ment, whereas unmodified MSCs failed [20,21]. Since ex-
pression levels of therapeutic peptides by MSCs can be
increased as much as 2,000-fold by viral transduction [20],
genetic modification provides the opportunity to achieve
effective treatment with a very much smaller dose of cells.
To test whether segmental therapy with engineered
MSCs can relieve neuropathic pain, we examined the
efficacy and limitations of DRG transplantation of MSCs
following experimental nerve injury. To provide enhanced
analgesic efficacy and in vivo tracking of transplanted cells,
a lentivector was constructed containing a viral 2A
ribosomal skipping domain to genetically modify MSCs
for co-expressing two proteins [22]. Glial cell line-derived
neurotrophic factor (GDNF) was chosen as the secreted
analgesic factor since it has well established and potent
analgesic properties [23-25], while enhanced green fluor-
escent protein (EGFP) was chosen for cell identification
and tracking. In vivo viability of MSCs and their effective-
ness in pain relief were evaluated by injection of these
genetically engineered cells into the fourth and fifth lum-
bar (L4 and L5) DRGs of rats at the time of peripheral
nerve injury induced by spinal nerve ligation (SNL).
Methods
Animals
Male Sprague Dawley rats (5–6 weeks old; 125–150 g body
weight) were purchased from Charles River Laboratories
(Wilmington, MA). All animal procedures were reviewed
and approved by the Animal Care Committee of the
Zablocki VA Medical Center Animal Studies Subcommit-
tee and Medical College of Wisconsin IACUC (Permission
number: 3690–03). Rats were housed in standard 12-hour
cycle lighting and were allowed ad libitum access to
food and water prior to and throughout the experimen-
tal protocol.Cell culture
Rat MSCs isolated from bone marrow of Sprague Dawley
(SD) rats at ≤ 8 weeks after gestation, were obtained from
Life Technologies (Carlsbad, CA, Lot No. 090716W01).
According to the vendor, these were frozen at 4th passage,
and express flow-cytometry cell surface markers CD29,
CD44, CD90, and CD106 (>70%) but are negative for
CD11b, CD34, and CD45 (<5%). Their ability to differenti-
ate into osteocytes, adipocytes, and chondrocytes has been
experimentally validated [26,27]. We therefore used the
cells for the subsequent experiments without further
characterization. Cells were cultured in low-glucose α-
MEM glutamax supplemented with 10% MSC-qualified
FBS and 1X antibiotic-antimycotic mixture (Life Tech-
nologies) and were maintained in humidified incubators at
37°C with 5% CO2. Upon reaching 70 ~ 80% confluency,
adherent cells were passaged by use of TrypLE Express
(Life Technologies). MSCs were expanded from 6 to 10
passages for all experiments. Pheochromocytoma-derived
(PC12) and HEK293T cell lines were obtained from the
American Type Culture Collection (ATCC, Manassas,
VA) and were cultured in standard conditions.
Lentiviral constructs and infection
Lentiviral transfer plasmids pEF1α-EGFP and pEF1α-
GDNF were used to express EGFP and GDNF, respect-
ively, as prior described [28]. A viral 2A bicistronic len-
tiviral plasmid for co-expressing rat GDNF and EGFP
under the EF1α promoter was constructed. Specifically,
rat GDNF cDNA coding sequence (GenBank accession
number, NM_199231) with omission of stop code was
inserted into plasmid pEF1α-EGFP immediate down-
stream of EF1α promoter and a viral 2A autocleavage
(or ribosome-skipping) sequence from Thoseaasigna
virus 2A was then cloned in frame between GDNF and
EGFP to generate pEF1α-GDNF-2A-EGFP. Lentivectors
(LV) expressing EGFP (LV-EGFP) and GDNF (LV-GDNF)
or co-expressing GDNF and EGFP (LV-GDNF-2A-
EGFP) were packaged using pEF1α-EGFP, pEF1α-
GDNF and pEF1α-GDNF-2A-EGFP with packaging plas-
mid pCMVΔR8.74 and envelop plasmid pVSV-g, followed
by lentiviral particle concentration by ultracentrifugation,
and viral titration by fluorescence-activated cell sorting
(FACS) or qPCR, as previously reported [28]. The titers
were in the range of 1 × 108 to 1 × 109 TU/ml. Cultured
MSCs grown to 50% confluence were infected by LV-
EGFP or LV-GDNF-2A-EGFP in the presence of 8 μg of
polybrene (Sigma-Aldrich, St Louis, MO) per ml at multi-
plicities of infection (MOI) = 20. After infection at 37°C
for 10 h, the medium was replaced. Mock transduction
was performed under the same conditions but without
added virus. Transduction efficiency was estimated under
a fluorescent microscope by calculating the percentage of
green cells out of total 200 counted cells. PC12 cells were
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EGFP, respectively, following the same procedure.
Measurement of GDNF secretion in cell cultures
To measure GDNF secretion by PC12 cells and MSCs
transduced by various LV constructs, equal numbers
(1x105) of non-transduced cells and LV transduced stable
cells were plated at 50% confluence. The media were col-
lected after 72 h and the concentration of GDNF in cul-
ture media were analyzed using an ELISA kit (Promega,
Madison, WI) conducted in 96-well microplates according
to the manufacturer’s instructions.
Immunoblots
Cell lysates were analyzed to determine transgene expres-
sion as described previously [28]. DRGs were harvested 3
weeks after transplantation with MSCs transduced with
LV-GDNF-2A-EGFP, and transgene expression (GDNF-
2A and EGFP) was determined by immunoblots using the
optimized GDNF antibody with a dilution that can only
detect GDNF-2A derived from the transplanted cells but
not endogenous GDNF. Briefly, 20μg of protein from
DRG homogenates was loaded onto SDS–PAGE, trans-
ferred, and probed with a monoclonal anti-GFP antibody
(1:1000, Santa Cruz Biotechnology, SCB, Santa Cruz, CA)
or rabbit polyclonal anti-GDNF antibody (1:1000, SCB).
Immunoreactive proteins were detected by enhanced
chemiluminescence (Pierce, Rockford, IL, USA) after incu-
bation with HRP-conjugated anti-mouse or anti-rabbit
IgG (1:2000, SCB). α-Tubulin (TUBA) was used as a load-
ing control.
Cell transplantation into DRGs
Cultured engineered MSCs were detached by incubation
with TrypLE and centrifuged at 400 g for 5 min, after
which the pelleted MSCs were resuspended in the steril-
ized PBS, viability determined by trypan blue, and cell
numbers counted by hemocytometer and adjusted to 107
per ml. Since both SNL and DRG injection of MSCs in-
volves surgery at the same site, the procedures were per-
formed at the same time in order to avoid the added
trauma and uncertain results of performing one or the
other in the setting of local scaring and adherent tissues.
DRG injection of MSCs into allogeneic rat recipients
was performed as described previously with minor
modification [13]. Briefly, the lateral aspects of the L4
through L6 vertebrae were surgically exposed, and a
minimal foraminotomy was performed to expose the
distal pole of the L4 and L5 DRGs. An injection volume
of 2μl per ganglion was chosen on the basis of previous
findings [13]. A total load of 2×104 cells per DRG was
injected based on a pilot experiment with injections of
1×104 to 3×104 cells, which showed that this number
provided widespread distribution in DRG 1 week afterinjection. Injection was performed through a pulled glass
micropipette with a tip diameter of 60-80 μm, which
allowed resuspended MSCs to be injected through a
micropipette without mechanical damage (data not
shown). The surgical incision was closed in layers with
absorbable suture and skin staples, which were removed
after 7–10 days.
Immunohistochemistry (IHC) and imaging
IHC staining on paraffin-embedded sections was per-
formed by a standard fluorescent IHC protocol, as previ-
ously described [28]. Sections were immunolabeled with
the primary antibodies of monoclonal GFP (1:400, SCB) or
rabbit polyclonal GFP (1:400, Cell Signaling, Danvers,
MA), monoclonal β3-tubulin (TUBB3, 1:500, SCB), rabbit
anti-glutamine synthetase (GS, 1:600, SCB), monoclonal
proliferating cell nuclear antigen (PCNA, 1:200, SCB),
rabbit anti Bcl-associated X protein (Bax, 1:100, SCB),
rabbit polyclonal GDNF (1:400, SCB), monoclonal STRO-1
(1:200, Life Technologies), rabbit polyclonal glial fibrillary
acidic protein (GFAP, 1:4000, Dako, Carpinteria, Califor-
nia), and α-smooth muscle actin (SM actin, Sigma-Aldrich,
1:1000), with BSA replacement of the first antibody as the
negative control. The appropriate fluorophore-conjugated
(Alexa 488 or Alexa 594) secondary antibodies (Jackson
ImmunoResearch, West Grove, PA) were used to reveal
the primary antibodies. The sections were examined and
images captured using a Nikon TE2000-S fluorescence
microscope (El Segundo, CA) with filters suitable for se-
lectively detecting the green and red fluorescence, and a
QuantiFire digital camera (Optronics, Santa Barbara, CA).
Experimental peripheral nerve injury and behavioral
testing
Peripheral nerve injury by the SNL model [29] was in-
duced in isoflurane-anesthetized animals with tight
ligation of the right L5 spinal nerves between the DRG
and the beginning of the spinal nerve. Sensory testing was
performed in a blinded fashion. Mechanical allodynia was
assessed by von Frey test using calibrated filaments with
the up-down method [30]. Mechanical hyperalgesia was
assessed by noxious punctate mechanical stimulation (pin
test) [31], in which a 22g spinal anesthesia needle was ap-
plied to the hind paws with enough force to indent, but
not puncture, the skin. Stimulations were applied 5 times
to each hindpaw, in an alternating pattern. This was then
repeated after at least 2 minutes, for a total of 10 stimula-
tions. Response was either a brief, simple withdrawal of
the paw with an immediate return to the cage floor, or a
response characterized by sustained lifting and grooming
of the affected paw, possibly with shaking, lasting at least
1 second. The latter behavior has been termed hyperalge-
sia behavior, and is associated with an aversive experience
in the context of peripheral nerve injury [32]. The number
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(out of 10 stimulations) was recorded.
Statistics
For comparison of behavior between groups, data were
converted to area under the curve for each animal. Planned
comparisons were tested between groups by t-test and
were corrected for multiple comparisons with Bonferroni
correction. Statistics were performed using GraphPad
Prism 6.03 (GraphPad Software La Jolla, CA). Results are
reported as mean and standard deviation. A probability of
p < 0.05 was considered as significant.
Results
Efficient generation of stable GDNF-secreting and
EGFP-labeled MSCs by a bicistronic lentivector
In order to engineer MSCs to express two transgene
products, we developed a lentivector LV-GDNF-2A-EGFP
that contains a viral 2A bicistronic transgene cassette to
co-express the analgesic peptide GDNF as well as EGFP
(Figure 1A). Simultaneous expression of both genes and
cleavage efficiency was confirmed in 293T cells by immu-
noblots of lysates transfected by LV-GDNF-2A-EGFP
plasmids, with GDNF and GNDF-EGFP fusion plasmid
transfections as controls (Figure 1B). Using this cassette,
GDNF protein secretion was evaluated in neuron-like
PC12 cells transduced with LV-GDNF-2A-EGFP, com-
pared with transduction by LVs encoding only GDNF or
EGFP. The media collected from these cultures demon-
strated efficient GDNF secretion using ELISA analysis
(Figure 1C). These results demonstrate the ability to de-
liver proteins with different final destinations from a single
2A bicistronic construct, i.e., secreted GDNF peptide for
therapy and intracellular EGFP label for identifying trans-
plantable cells. We next tested the ability of MSCs trans-
duced by LV-GDNF-2A-EGFP to produce stable GDNF
secretion and EGFP expression in MSCs. Both immuno-
histochemistry (Figure 1D) and immunoblot of the cell ly-
sates (Figure 1E) demonstrated expression of both EGFP
and GDNF by the LV-GDNF-2A-EGFP transduced MSCs,
while no GDNF was found in cells or lysate of naïve
MSCs. ELISA (Figure 1F) showed that LV-GDNF-2A-
EGFP transduced cells secreted GDNF at a 5-fold greater
rate than native MSCs.
Survival and integration of engineered MSCs in DRG
We first determined if MSCs can survive after trans-
plantation into DRGs of adult rats. Whereas fluorescent
dyes such as DAPI are not a reliable marker for MSCs
in vivo [33], GFP expression provides definitive tracking
of surviving MSCs [34]. Therefore, we transduced the
MSCs with LV-EGFP (hereafter referred to as EGFP-
MSCs) or with LV-GDNF-2A-EGFP (hereafter referred
to as GDNF/EGFP-MSCs). The transduction of MSCs bylentivectors was optimized at MOI = 20, at which level
more than 90% of MSCs were successfully transduced. To
assess MSC survival, differentiation, and integration into
DRGs, we transplanted engineered allogeneic cells into the
L4 and L5 DRGs in adult non-injured rats. The recipient
rats were euthanized at 1, 2, 3 and 4 weeks post-
transplantation and DRG sections were analyzed by
immunofluorescence staining of transgenes.
EGFP-MSCs
In DRGs harvested 1 week after injection of EGFP-MSCs,
numerous transplanted EGFP-expressing MSCs were ob-
served in DRG sections, showing typical fibroblast-like
morphology (Figure 2A, B). In general, the transplanted
EGFP-MSCs were distributed in the extracellular matrix
space without disrupting the normal pattern of satellite
glial cell apposition to sensory neurons, suggesting well-
tolerated integration of engrafted MSCs into DRG tissue.
No EGFP-MSCs were found by IHC in the contralateral
DRGs or the spinal cord (data not shown). Although it is
impossible to accurately count surviving cells because
of their aggregation, it was clear that fewer EGFP-expressing
MSCs were evident 3 weeks post-transplantation (Figure 2C,
D), while they retained morphology similar to that at 1 week
post-transplantation. No engrafted MSCs were found by
IHC in the recipient DRGs 4 weeks after transplantation
(n = 10 DRGs).
Immunofluorescence was performed to determine the
differentiation potentials of transplanted MSCs within
the environment of the DRG. EGFP-MSCs were immu-
nopositive for STRO-1 (an MSC marker, Figure 2E).
MSCs did not express satellite glial cell marker GS
(Figure 2F) or GFAP (Figure 2G). No MSCs were found
to be positive for β3-tubulin, a sensory neuron marker
(Figure 2H). Consistent with in vitro cultured cells (data
not shown), engrafted MSCs also expressed proliferating
cell nuclear antigen (PCNA, Figure 2I), and immunoposi-
tivity for pro-apoptosis regulator Bax [35] (Figure 2J),
which together indicate active cell cycling. Overall, these
results indicate that MSCs can survive within DRGs for
2–3 weeks after transplantation under the conditions of
this experiment, and that the surviving transplanted MSCs
retained their primary MSC properties without spontan-
eous differentiation to neuronal or glial cell types in the
DRG microenvironment during the period of observation.
GDNF/EGFP-MSCs
We next evaluated survival of GDNF-secreting MSCs (i.e.
GDNF/EGFP-MSCs) after DRG transplantation. Although
others have identified enhanced survival of MSCs in the
presence of GDNF [36], our findings showed that GDNF-
expressing MSCs had the similar survival pattern (Figure 3A,
B) as was seen for MSCs expressing EGFP alone. Immu-
nostaining (Figure 3A-G) similarly revealed that GDNF
Figure 1 Generation of GDNF-secreting MSCs. (A) Schematic diagram illustrates the key elements of the lentiviral plasmid containing a viral 2A
bicistronic transgene cassette (2A peptide depicted below with an arrowhead denoting the cleavage site) to co-express EGFP and GDNF driven by a
short EF1α (sEF1α) promoter. Cis-acting sequences contain cPPT (central polypurine tract) and WPRE (woodchuck posttranscriptional regulatory element).
(B) Immunoblots of HEK293T lysates for GDNF (top panel) or EGFP (middle panel) transfected with the lentiviral plasmids carrying the following
transgenes: HEK293 (lane 2), EGFP (lane 3), GDNF (lane 4), GDNF-EGFP fusion (lane 5), and two GDNF-2A-EGFP constructs (lane 6,7). Various protein
bands are denoted along the right side of the panels. Native GDNF appears as two bands due to the variable retention or cleavage of the signal
peptide portion. The bands for GDNF-2A are approximately 5KDa heavier than GDNF due to retention of the 2A peptide up to the cleavage site.
Alpha-tubulin (TUBA) was used as the protein loading control (bottom panel). (C) PC12 cells were transduced using lentivectors (LV) expressing
EGFP, GDNF, or GDNF-2A-EGFP, respectively. ELISA analysis of media demonstrates an efficient GDNF secretion from the cells transduced with
LV-GDNF-2A-EGFP, similar to LV-GDNF transduction, whereas secretion is minimal in controls (PC12 or PC12 transduced with LV-EGFP). n = 4 for
each group, ***p < 0.001. (D) Immunocytofluorescence shows minimal GDNF expression in MSCs transduced by LV-EGFP, while MSCs transduced
by LV-GDNF-2A-EGFP develop substantial GDNF expression 3 days after transduction (scale bar = 100 μm). (E) Immunoblots of cell lysates of MSCs
transduced with LV-GDNF-2A-EGFP show EGFP and GDNF expression, which is absent in naïve MSCs. (F) ELISA of media shows that naïve MSCs
secreted low levels of GDNF, which increased five-fold in the MSCs after LV-GDNF-2A-EGFP transduction, n = 4 for each group, ***p < 0.001.
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Figure 2 Survival and differentiation of transplanted EGFP-MSCs in the non-injured DRGs. Immunohistochemical preparations reveal
transplanted EGFP-MSCs in DRG sections, showing numerous EGFP-MSCs with typical fibroblast-like morphology and some MSC migrating in a
short distance along roots and sciatic nerve 1 week after transplantation (A, outlined area magnified in B), but reduced numbers of engrafted
EGFP-MSCs 3 weeks after transplantation (C, D). Here and in subsequent panels, filled arrowheads point to the engrafted EGFP-MSCs, and empty
arrowheads indicate EGFP-negative neurons or satellite glia. Transplanted MSCs retained STRO-1 expression typical of MSCs (E). EGFP-MSCs
(green) show a general distribution pattern in the extracellular matrix space, without disrupting the normal relationship in which satellite glia,
stained here by GS (red), form rings enwrapping sensory neurons (unstained here, F). Identification of satellite glial cells by GFAP provides similar
findings (G). Transplanted EGFP-MSCs do not express GS (F) or GFAP (G). Sensory neuron somata, labeled by TUBB3 (red), are typically separated
from MSCs (stained with EGFP) that are negative for TUBB3 (H). Engrafted EGFP MSCs express immunopositivity for proliferating cell nuclear
antigen (PCNA) (I) and pro-apoptosis regulator Bax (J). Scale bar = 50 μm for all images. Sections were harvested 1 week after transplantation in
panels E, F, H, and J, and were harvested 3 weeks after transplantation in panels G and I.
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profile and marker expression after transplantation.
Analgesia from MSC engraftment
In the absence of injury, injection of EGFP MSCs caused
negligible behavioral changes in either threshold for
withdrawal from mechanical stimulation with von Freyfibers or the rate of hyperalgesia-type responses upon
fully noxious stimulation by Pin (Figure 4A), suggesting
preservation of normal mechanosensory neuron function
in the presence of MSCs and minimal injury or inflam-
mation due to the procedure. To test the efficacy of
engineered MSCs as a treatment for neuropathic pain,
animals were transplanted with either EGFP-MSCs or
Figure 3 Survival of transplanted GDNF/EGFP-MSCs in the non-injured DRGs. Integrated GDNF/EGFP-MSCs are shown residing in extracellular
spaces within DRGs at 1 week (A) and 2 weeks (B) post-transplantation using GDNF and GFP antibodies. High-power image (C) of DRG 2 weeks after
transplantation reveals high expression of GDNF and GFP in fibroblast-like GDNF/EGFP-MSCs while the endogenous GDNF immunofluorescent (IF)
signals are detected as ‘glia-rings’ around neurons and variably in neurons. Double immunostaining 2 weeks after transplantation shows that the
grafted GDNF/EGFP-MSCs are immunopositive for STRO-1 (D) but immunonegative for Tubb3 (E), GS (F), and GFAP (G). In C-G, the filled arrowheads
denote engrafted GDNF/EGFP-MSCs, while the empty arrowheads indicate endogenous markers. Scale bar = 50 μm for all images.
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Both L4 and L5 DRGs were injected since the etiology of
pain after SNL may involve contributions from both theaxotomized neurons of the L5 DRG as well as the intact
adjacent L4 neurons [37]. Mechanical allodynia (von
Frey) and hyperalgesia (Pin) developed by one week after
Figure 4 Analgesic effects from GDNF-secreting MSC engraftment. (A) In the absence of injury, transplantation of EGFP-MSCs did not
change the frequency of hyperalgesia response upon fully noxious stimulation by Pin (top panel) or the threshold for withdrawal from mechanical
stimulation with von Frey fibers (bottom panel). (B) In the setting of neuropathic pain from L5 SNL, animals transplanted with either type of cells
(EGFP-MSCs or GDNF/EGFP-MSCs) at the time of nerve injury all developed mechanical hyperalgesia (Pin) and allodynia (von Frey) by 7 days later
(left panels), which persisted for 21 days. However, those animals receiving GDNF/EGFP-MSCs showed a smaller reduction in withdrawal threshold,
demonstrated by area under the curve (AUC) analysis comparing groups (right panel), *p < 0.05. (C) Immunoblots show detection of GDNF-2A
(top panel) and EGFP (middle panel) derived from transplanted GDNF/EGFP-MSCs in DRGs (from 2 different animals) harvested 3 weeks after
transplantation, while endogenous GDNF was not detected in control DRGs contralateral to the injury.
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4-week duration of the experiment. However, those ani-
mals receiving GDNF/EGFP-MSCs developed a signifi-
cantly smaller reduction in withdrawal threshold and
smaller elevation in hyperalgesia responses compared
to animals receiving EGFP-MSCs (Figure 4B). We add-
itionally compared behavior of animals receiving SNL
plus MSC transplantation to those receiving SNL with
only saline injection into the DRGs, which showed that
hyperalgesia was reduced with GDNF/EGFP-MSCs but
not by EGFP-MSCs. To test for possible extended anal-
gesia from GDNF/EGFP-MSC transplantation, we ex-
amined additional animals (EGPF-MSCs n = 5, GDNF/
EGFP-MSCs n = 3) at 4 weeks, which showed no differ-
ence in either hyperalgesia (Pin, p = 0.11) or allodynia
(von Frey, p = 0.36). MSCs were not evident by IHC in
the serial sections from any DRGs in these animals. To-
gether, these results indicate that MSCs expressing
EGFP alone did not provide analgesia, whereas trans-
plantation of MSCs engineered to secrete GDNF re-
duces pain behavior after nerve injury. Immunoblots
using GDNF and GFP antibodies, collected at 3 weeks
after transplantation, validated the production of GDNF
by transplanted cells in the DRGs injected with GDNF/
EGFP-MSCs, whereas the contralateral control DRGs
showed no endogenous GDNF using optimized im-
munoblotting conditions (1:1000 dilution for GDNF
antibody, Figure 4C).
Overgrowth of transplanted MSCs in DRG
Accumulation of engrafted MSCs was observed in 12%
of DRGs subjected to MSC transplantation and SNL
(n = 8 out of 66 DRGs), forming a nodule within DRGs
3 or 4 weeks after injection with either EGFP-MSCs(n = 1 axotomized L5 DRGs and n = 2 adjacent L4
DRGs) or GDNF/EGFP-MSCs (n = 3 L5 and n = 2 L4
DRGs). Sensory evaluation of these 8 rats, which were ex-
cluded from the behavior analysis, showed anesthesia dur-
ing mechanical stimulation in four of them, suggesting
sensory function was adversely affected by the MSC mass.
Hematoxylin & eosin staining of DRG sections (Figure 5A,
B) revealed a hypercellular accumulation of MSCs within
the DRG, consisting of pleomorphic cells with normal sen-
sory neurons and axons surrounding the cellular mass or
dispersed in the MSC stroma. Immunohistochemical exam-
ination revealed that the cellular nodule is composed of
EGFP-positive cells that exhibit generally typical morph-
ology of MSCs and immunopositivity for STRO-1 but
negative for TUBB3 (Figure 5C, D), GFAP (Figure 5E, F),
and α-smooth muscle actin (not shown). These MSCs
expressed PCNA (Figure 5G) and were immunopositive for
Bax (Figure 5H), similar to the population of MSCs un-
associated with mass formation (Figure 5I, J). These results
indicate that the MSCs that compose the nodular mass re-
tain the phenotype of primary MSCs without definite cell
transformation, and are not immunohistochemically
distinct from MSCs that did not excessively proliferate.
Discussion
A multitude of mechanistic observations have emerged
from research on chronic pain, but these discoveries
have not led to successful therapies. Genetic treatment
strategies may provide a critical breakthrough to take ad-
vantage of molecular discoveries on the underlying causes
of chronic pain. While using viral vectors to deliver trans-
genes to neural tissue may lead to highly specific treat-
ments, this approach has inherent limitations, including
unavoidable risks of activating the host immune system,
Figure 5 Tumor-like aggregation of transplanted MSCs within DRG. (A, B) Representative images from one of the DRGs in which MSC
transplantation led to development of a mass show hematoxylin & eosin (H&E) stains of a tumor-like mass in a DRG from a EGFP MSC recipient
rat (SNL), revealing a hypercellular aggregations of MSCs consisting of pleomorphic cells, with normal sensory neuron somata and axons mostly
surrounding the mass (A) but also some dispersed within the MSC stroma (B, arrows). Immunohistochemical examination shows the cellular
nodule is composed of EGFP-positive cells that are negative for TUBB3 (C, outlined area magnified in D, arrows point TUBB3-positive neurons) and
GFAP (E, outlined area magnified in F). These MSCs express high level of PCNA (G) and immunopositivity for Bax (H). Scale bars: A-F = 100 μm,
G, H = 50 μm.
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vation, and of generation of replication-competent virus
following administration. An alternate genetic approach
without these limitations would be very valuable. We have
evaluated the therapeutic potential of transplanting allo-
geneic MSCs into the DRG after they have been engi-
neered to secrete an analgesic peptide, thereby functioning
as biological mini-pumps for the treatment of neuropathicpain. Our findings show encouraging results and pro-
vide evidence that cell therapy at the level of the DRG,
using genetically modified MSCs, may potentially be
developed for treating chronic neuropathic pain.
A prior attempt at DRG transplantation of unmodified
MSCs used a nuclear stain for identifying MSCs [38],
but this technique allows transfer of the staining dye to
host cells after MSC death [39], and sections revealed
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satellite glial cells, while analgesia was seen only at 3 days
after transplantation. In contrast, our labeling method by
EGFP expression assures certain identification of the sur-
viving engrafted MSCs, and additionally confirms transgene
expression by the engineered cells. Thus, this report is the
first to conclusively demonstrate the analgesic potential of
cell-mediated analgesia by targeted DRG injection. We used
a model of peripheral nerve injury that has relevance to
clinical conditions such as surgical nerve injury at the time
of amputation, in which early preemptive treatment may
limit the development of neuropathic pain. In this study,
we did not observe pain attenuation in injured rats with
EGFP-MSC transplantation, while GDNF-secreting MSCs
provided moderate pain suppression. This supports an in-
terpretation that analgesia after DRG injection of GDNF-
secreting MSCs is attributable to their production and
secretion of GDNF.
We observed MSC survival for up to 3 weeks, although
there is a fall-off of cell numbers. Since this treatment
strategy for chronic pain requires MSC survival to provide
continued secretion of the therapeutic peptide, cell loss
could result in a decrement of analgesia. Therefore, sur-
vival of allografted MSCs would be an important obstacle
for successful long-term cell-based therapy for chronic
pain. Allogeneic MSCs have long been reported to be non-
immunogenic [40]. However, recent studies describe lim-
ited allogeneic MSC survival and generation of antibodies
against allogeneic donor MSCs after transplantation into
immunocompetent recipients [40-46]. This suggests that
MSCs may not intrinsically be immuneprivileged, and that
our observation of cell loss is attributable to immuno-
logical rejection. Other DRG environmental factors that
may limit longevity of transplanted MSCs include periph-
eral nerve injury-induced inflammatory response, oxida-
tive stress conditions, and presence of pro-apoptotic
factors and chemokines, and factors during initial cell cul-
ture condition and passage number may also play a role
[39,47]. These mechanisms may not be mutually exclusive,
and together may influence the survival of transplanted
cells. It is reported that clonally grown MSC subpopula-
tions may be identified with greater survival [48]. Further
studies could identify desirable biological properties and
their markers in cultured MSC subpopulations before ex-
pansion and transplantation [49]. A promising alternative
is the potential of substantially improving survival through
the use of autotransplantation [50,51]. Since MSCs can be
cultured from bone marrow or adipose tissue [52] and
propagate rapidly, generating the relatively small population
needed for transplantation into DRGs would be feasible in
the clinical setting even when using MSCs originating from
the patient’s own tissue.
Our data also show that engineering MSCs by LV trans-
duction enabled them to secrete GDNF. Transplantationof these GDNF-secreting MSCs provided an antihyperal-
gesic effect compared to similarly injured animals receiv-
ing saline injection, while MSCs expressing EGFP alone
did not, which indicates that the treatment effect is due to
the secretion of GDNF, not simply the presence of MSCs
per se. The therapeutic mechanism of GDNF may involve
prevention of injury-induced ectopic neuronal activity
by preventing shifts in the expression of voltage-gated
Na+ channel subtypes in DRG neurons [23,53]. Prior
findings using lentiviral-mediated GDNF expression [54] in-
dicate that the predominant source of analgesia may be
from actions of GDNF on the intact L4 neurons after SNL
rather than the axotomized neurons of L5. This key role of
the transgene also suggests that development of this treat-
ment approach could employ a wide range of analgesic
peptides such as inhibitory neurotransmitters (e.g. beta-
endorphin [55], anti-inflammatory peptides (e.g. IL-10 [21],
fractalkine [56]) neurotrophins (NT-3 [55], VEGF [57]),
and soluble receptors (e.g. soluble tumor necrosis factor
receptor [58]) to treat various chronic pain conditions.
It is unclear why others [38] have observed analgesia
resulting from transplantation of non-engineered MSCs,
in contrast to our findings. This may be attributable to
the exact nature of the MSCs. For instance, culture con-
ditions and passage number may be factors that affect
the biological function of different cell preparations [49].
In support of this concept, intrathecal application neural
stem cells has been shown to alleviate neuropathic pain
in rats through release of GDNF [12], but another report
shows that SNL-induced pain behavior in rats is not
reduced by intrathecal 15-passage MSCs [59].
Biosafety is a critical concern that could limit develop-
ment of MSC-based therapy for pain. Therefore, a prob-
lematic observation from this study is the development of
an MSC mass in 12% of recipient DRGs at 3-4 weeks
post-transplantation. While it is reported that MSCs se-
creting transgenic GDNF may have higher rates of en-
graftment and survival [36], we doubt that this was a
factor in the production of a mass since we also observed
accretions of MSCs that expressed only EGFP. The results
showing both occasional formation of a highly proliferat-
ing cellular mass in some DRGs but also a generally lim-
ited MSC survival duration in the majority of recipient
DRGs may reflect the heterogeneous nature of the MSCs
used in this study. It is well-recognized that MSCs consti-
tute a non-uniform population of stromal cells [60].
Additionally, ex vivo culture of MSCs can induce spon-
taneous genome instability and alterations of functional
and biological properties in some lineages of MSCs, leading
to buildup of genetic aberrations to become tumorigenic
clones with a growth advantage [61]. Indeed, tumorigenesis
of transplanted allogeneic MSCs in various targeted tissues
has been observed [61-64]. Some reports of tumorigenesis
have subsequently been attributed to cross-contamination
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did not likely contribute to the formation of MSC masses
in our series since there were no exogenous tumor cells in
the environment where the MSCs were cultured. Finally,
there is a potential risk that lentivector genetic modification
may induce transformation by activating oncogenes due to
promoter insertion [67]. However, extensive studies have
shown that lentiviral vectors have a low tendency to inte-
grate in places that potentially cause tumor and are well
suited for safe and effective clinical gene transfer [68,69].
Overall, MSC tumorigenicity provoked by lentivector-
transduction has been considered to be low [48,70]. Since
MSCs similar to those used in the present study did not
form masses when implanted into the brain [39,71], the
specific molecular microenvironment of the DRG, particu-
larly following peripheral nerve injury, may be a factor con-
tributing to occasional excessive propagation.
In conclusion, our initial findings demonstrate that seg-
mental pain therapy with DRG transplantation of genetic-
ally modified MSCs can provide therapeutic benefit for
neuropathic pain. Important challenges for developing this
method include characterizing parameters that influence
MSC cell cycle and proliferation, prolonging in vivo MSC
survival, and preventing the occasional development of
tumor-like aggregations of transplanted cells. With these
advances, engineered MSCs may offer a novel opportunity
for cell-based gene therapy that could provide safe, sus-
tained segmental therapy for treating chronic pain.
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